Skip to main content

Table 1 Inclusion and exclusion criteria for SU add-on systematic review

From: A systematic review and mixed-treatment comparison of dapagliflozin with existing anti-diabetes treatments for those with type 2 diabetes mellitus inadequately controlled by sulfonylurea monotherapy

Inclusion criteria Description
Population Adults (aged ≥18 years) with T2DM on a stable dose of a SU as monotherapy (for at least 8 weeks, at half the maximum dose or maximum tolerable dose) where SU alone, with diet and exercise, does not provide adequate glycaemic control.
Treatment pathway Add-on pharmacological therapy after failure of SU monotherapy, where the first-line SU was initiated because metformin was considered inappropriate.
Interventions Pharmacological therapies that would be added to a SU in clinical practice when SU monotherapy does not provide adequate glycaemic control.
Comparators Active arms: Dual therapies of interest namely drugs/doses licensed in the EU, as a dual therapy in combination with a SU and as used in clinical practice[13].
Outcomes To be included in the meta-analysis, studies needed to report at least 1 of the primary endpoints of interest at 24 +/- 6 weeks:
  • mean change in HbA1c from baseline
  • mean change in weight from baseline
  • mean change in systolic blood pressure from baseline
  • proportion (number) of patients experiencing at least 1 hypoglycaemia episode
  Interim results from longer-term studies were permitted provided that dose titration and a sufficient maintenance period were complete at follow-up.
Study design • Prospective, RCTs.
  • If cross-over design then results reported prior to the cross-over period can be used in the meta-analysis.
  • Minimum follow-up of 18 weeks to be included in the meta-analysis (i.e. 24 weeks +/-6 weeks); an expansion of the study window to 24 +/- 8 weeks as a sensitivity analysis for borderline studies was permitted.
Publications Full-text publications, except for abstracts published in 2012 (for results from recently completed trials), full-text available in English.
Exclusions • Results from uncontrolled open label extensions of RCTs.
  • Studies of SU used as part of a triple therapy regimen.
  • Study populations with moderate to severe renal impairment.
  • Study arms using treatment dosing regimens that are not licensed in the EU.
  1. EU, European Union; Hba1c, glycated haemoglobin; RCT, randomised-controlled trial; SU, sulfonylurea; T2DM, type 2 diabetes mellitus.